ArticleCureus2024

Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series.

Takayuki Shimamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.